107 related articles for article (PubMed ID: 16549112)
1. Purine analogues in advanced T-cell lymphoid malignancies.
Kurzrock R; Ravandi F
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S27-34. PubMed ID: 16549112
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Tsimberidou AM; Giles F; Duvic M; Fayad L; Kurzrock R
Cancer; 2004 Jan; 100(2):342-9. PubMed ID: 14716770
[TBL] [Abstract][Full Text] [Related]
3. Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas.
Dearden CE
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S22-6. PubMed ID: 16549111
[TBL] [Abstract][Full Text] [Related]
4. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
5. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
6. Purine analogue combinations for indolent lymphomas.
Di Bella N; Ravandi F
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S11-21. PubMed ID: 16549109
[TBL] [Abstract][Full Text] [Related]
7. CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
Sato K; Dang NH
Int J Oncol; 2003 Mar; 22(3):481-97. PubMed ID: 12579300
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with purine nucleoside analogs.
Foss FM
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):31-5. PubMed ID: 10887642
[TBL] [Abstract][Full Text] [Related]
9. Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
Kay NE
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S50-4. PubMed ID: 16549115
[TBL] [Abstract][Full Text] [Related]
10. Pentostatin (Nipent) in T-cell lymphomas.
Kurzrock R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):64-6. PubMed ID: 10877055
[TBL] [Abstract][Full Text] [Related]
11. Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia.
Lamanna N; Weiss MA
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S44-9. PubMed ID: 16549114
[TBL] [Abstract][Full Text] [Related]
12. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.
Mercieca J; Matutes E; Dearden C; MacLennan K; Catovsky D
J Clin Oncol; 1994 Dec; 12(12):2588-93. PubMed ID: 7989933
[TBL] [Abstract][Full Text] [Related]
13. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
14. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.
Osuji N; Matutes E; Tjonnfjord G; Grech H; Del Giudice I; Wotherspoon A; Swansbury JG; Catovsky D
Cancer; 2006 Aug; 107(3):570-8. PubMed ID: 16795070
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
17. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas.
Novakovic BJ; Novakovic S; Frkovic-Grazio S
Oncol Rep; 2006 Jul; 16(1):191-5. PubMed ID: 16786145
[TBL] [Abstract][Full Text] [Related]
18. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
20. Pentostatin for the treatment of indolent lymphoproliferative disorders.
Ho AD; Hensel M
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S2-10. PubMed ID: 16549110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
